Drug:
Reaction: THERAPY INTERRUPTED
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25120459 |
2 | ||
Hospitalisation, Therapy interrupted, |
||||
METHOTREXATE, ROSUVASTATIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, FAMOTIDINE, LEVOTHYROXINE SODIUM, |
||||
| 202 | 25120522 |
69 | 2 | |
Bronchitis, Therapy interrupted, |
||||
TOFACITINIB, TOFACITINIB, TOFACITINIB, |
||||
| 203 | 25120777 |
US |
||
Therapeutic product effect incomplete, Therapy interrupted, Condition aggravated, |
||||
APREMILAST, |
||||
| 204 | 25123177 |
44 | 2 | |
Illness, Therapy interrupted, |
||||
ABATACEPT, ABATACEPT, ABATACEPT, |
||||
| 205 | 25123250 |
54 | 2 | |
Urinary tract infection, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 206 | 25123260 |
69 | 2 | |
Gastroenteritis viral, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 207 | 25123270 |
1 | ||
Large intestinal obstruction, Therapy interrupted, Product distribution issue, |
||||
ADALIMUMAB-RYVK, ALLOPURINOL, |
||||
| 208 | 25123371 |
66 | 2 | |
Femur fracture, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 209 | 25123475 |
60 | 1 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 210 | 25123568 |
35 | 2 | |
Illness, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 211 | 25109890 |
US |
1 | |
Pruritus, Therapy interrupted, |
||||
APREMILAST, AMLODIPINE BESYLATE, |
||||
| 212 | 25110055 |
US |
1 | |
Therapy interrupted, Weight abnormal, |
||||
INFLIXIMAB-AXXQ, INFLIXIMAB-AXXQ, INFLIXIMAB-AXXQ, |
||||
| 213 | 25110182 |
US |
||
Neoplasm malignant, Hospice care, Therapy interrupted, |
||||
OSIMERTINIB, |
||||
| 214 | 25110300 |
US |
59 | 2 |
Haemorrhage, Limb injury, Device issue, Therapy interrupted, |
||||
BENRALIZUMAB, |
||||
| 215 | 25110365 |
US |
||
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 216 | 25110366 |
US |
||
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 217 | 25110666 |
US |
||
Diarrhoea, Therapy interrupted, |
||||
RELUGOLIX, RELUGOLIX, |
||||
| 218 | 25110770 |
US |
54 | 1 |
Device difficult to use, Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 219 | 25110971 |
US |
2 | |
Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 220 | 25111012 |
US |
||
Therapy interrupted, |
||||
BEVACIZUMAB-AWWB, |
||||
| 221 | 25111359 |
US |
83 | 1 |
Constipation, Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 222 | 25111385 |
GB |
1 | |
Psychotic disorder, Therapy interrupted, |
||||
CLOZAPINE, |
||||
| 223 | 25111465 |
US |
46 | 2 |
Haemoptysis, Tenderness, Contusion, Chest pain, Menstruation irregular, Nodule, Disorientation, Arrhythmia, Back pain, Injection site reaction, Epistaxis, Platelet count decreased, Dizziness, Headache, Off label use, Therapy interrupted, Insurance issue, |
||||
ENOXAPARIN SODIUM, PREDNISONE, APIXABAN, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, APIXABAN, |
||||
| 224 | 25111705 |
US |
70 | 2 |
Product prescribing issue, Therapy interrupted, |
||||
POMALIDOMIDE, |
||||
| 225 | 25112156 |
GB |
1 | |
Malaise, Therapy interrupted, |
||||
CLOZAPINE, |
||||
| 226 | 25112267 |
US |
1 | |
Product availability issue, Therapy interrupted, |
||||
BRIVARACETAM, |
||||
| 227 | 25112398 |
US |
2 | |
Product availability issue, Therapy interrupted, |
||||
BRIVARACETAM, |
||||
| 228 | 25112404 |
US |
||
Product availability issue, Therapy interrupted, |
||||
BRIVARACETAM, |
||||
| 229 | 25112539 |
US |
2 | |
Psoriasis, Drug ineffective, Product dose omission issue, Insurance issue, Therapy interrupted, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 230 | 25112600 |
US |
2 | |
Stress, Product distribution issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 231 | 25112606 |
US |
1 | |
Influenza like illness, Product availability issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 232 | 25112653 |
US |
1 | |
Skin disorder, Product availability issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 233 | 25112714 |
US |
1 | |
Product availability issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 234 | 25112764 |
US |
2 | |
Product availability issue, Therapy interrupted, Off label use, |
||||
BIMEKIZUMAB, |
||||
| 235 | 25112809 |
US |
2 | |
Drug ineffective, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 236 | 25112839 |
US |
2 | |
Rash, Illness, Nasopharyngitis, Cough, Product availability issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 237 | 25112918 |
US |
2 | |
Psoriasis, COVID-19, Viral infection, Aphonia, Fatigue, Therapy interrupted, Product availability issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 238 | 25112956 |
US |
65 | 1 |
Product dose omission issue, Therapy interrupted, Inability to afford medication, |
||||
BIMEKIZUMAB, |
||||
| 239 | 25112982 |
US |
2 | |
Insurance issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 240 | 25112989 |
US |
2 | |
Product use issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 241 | 25113086 |
US |
2 | |
Therapy interrupted, Inability to afford medication, |
||||
BIMEKIZUMAB, |
||||
| 242 | 25113174 |
US |
1 | |
Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 243 | 25113176 |
US |
2 | |
Insurance issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 244 | 25113190 |
US |
73 | 1 |
Oral candidiasis, Arthralgia, Inappropriate schedule of product administration, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 245 | 25113232 |
US |
47 | 1 |
Candida infection, Therapy interrupted, Insurance issue, |
||||
BIMEKIZUMAB, |
||||
| 246 | 25113234 |
US |
2 | |
Product availability issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 247 | 25113288 |
US |
50 | 1 |
Product availability issue, Therapy interrupted, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 248 | 25113315 |
US |
1 | |
Incorrect dose administered, Product supply issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 249 | 25113326 |
1 | ||
Weight decreased, Constipation, Blood potassium decreased, Therapy interrupted, |
||||
TAFAMIDIS, DAPAGLIFLOZIN, |
||||
| 250 | 25113512 |
PR |
85 | 2 |
Plasma cell myeloma, Product prescribing issue, Therapy interrupted, |
||||
LENALIDOMIDE, DENOSUMAB, |
||||
| 251 | 25113653 |
US |
2 | |
Poor quality product administered, Therapy interrupted, Product physical issue, |
||||
ICOSAPENT ETHYL, ICOSAPENT ETHYL, |
||||
| 252 | 25113666 |
US |
59 | 2 |
Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 253 | 25113733 |
US |
71 | 1 |
Off label use, Therapy interrupted, |
||||
ICOSAPENT ETHYL, |
||||
| 254 | 25113737 |
US |
49 | 1 |
Therapy interrupted, Poor quality product administered, Product odour abnormal, Product taste abnormal, Product physical issue, Product colour issue, |
||||
ICOSAPENT ETHYL, ICOSAPENT ETHYL, CETIRIZINE HYDROCHLORIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, LISINOPRIL, LISINOPRIL, ROSUVASTATIN, |
||||
| 255 | 25113739 |
US |
||
Therapy interrupted, Product physical issue, Product odour abnormal, |
||||
ICOSAPENT ETHYL, |
||||
| 256 | 25113748 |
US |
75 | 1 |
Poor quality product administered, Wrong technique in product usage process, Therapy interrupted, Product odour abnormal, Product physical issue, |
||||
ICOSAPENT ETHYL, ICOSAPENT ETHYL, |
||||
| 257 | 25113976 |
US |
2 | |
Parkinson^s disease, Therapy interrupted, Product availability issue, |
||||
ROTIGOTINE, |
||||
| 258 | 25113977 |
BR |
2 | |
Rheumatoid arthritis, Product distribution issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 259 | 25114473 |
US |
29 | 1 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 260 | 25114760 |
66 | 2 | |
SARS-CoV-2 test positive, Therapy interrupted, |
||||
ADALIMUMAB-ATTO, |
||||
| 261 | 25114876 |
61 | 2 | |
Influenza, Pneumonia, Atrial fibrillation, Therapy interrupted, |
||||
IMATINIB MESYLATE, IMATINIB, |
||||
| 262 | 25114934 |
79 | 1 | |
Sepsis, Therapy interrupted, |
||||
SECUKINUMAB, |
||||
| 263 | 25115313 |
US |
74 | 2 |
Embolism, Therapeutic response decreased, Osteoporosis, Therapy interrupted, |
||||
ABATACEPT, |
||||
| 264 | 25118132 |
18 | 2 | |
Product distribution issue, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 265 | 25118468 |
69 | 1 | |
Septic shock, Asthenia, Therapy interrupted, |
||||
RIOCIGUAT, |
||||
| 266 | 25118569 |
2 | ||
Therapy interrupted, Cardiac failure congestive, |
||||
AMBRISENTAN, |
||||
| 267 | 25118687 |
76 | 2 | |
Nasopharyngitis, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 268 | 25118693 |
27 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 269 | 25118753 |
76 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 270 | 25118774 |
57 | 1 | |
Osteomyelitis, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 271 | 25119080 |
83 | 1 | |
Hospitalisation, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 272 | 25119104 |
67 | 1 | |
Therapy interrupted, Illness, |
||||
ABATACEPT, |
||||
| 273 | 25119415 |
57 | 2 | |
Localised infection, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 274 | 25119553 |
59 | 2 | |
Surgery, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 275 | 25119607 |
42 | 2 | |
Influenza, Therapy interrupted, |
||||
IXEKIZUMAB, |
||||
| 276 | 25119679 |
37 | 2 | |
Pregnancy, Therapy interrupted, Inappropriate schedule of product administration, Product dose omission in error, Exposure during pregnancy, Maternal drugs affecting foetus, Abortion spontaneous, |
||||
RISANKIZUMAB-RZAA, |
||||
| 277 | 25109391 |
US |
51 | 2 |
Rheumatoid arthritis, Insurance issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, PREDNISONE, |
||||
| 278 | 25109587 |
US |
63 | |
Hepatic enzyme increased, Device difficult to use, Accidental exposure to product, Therapy interrupted, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 279 | 25109636 |
US |
71 | 2 |
Device difficult to use, Accidental exposure to product, Therapy interrupted, Incorrect disposal of product, |
||||
EVOLOCUMAB, |
||||
| 280 | 25109638 |
US |
86 | 1 |
Arthropathy, Insurance issue, Therapy interrupted, Needle issue, Drug ineffective, |
||||
ABATACEPT, ABATACEPT, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, HYDROXYCHLOROQUINE, GABAPENTIN, LOSARTAN, CLONAZEPAM, MELATONIN, |
||||
| 281 | 25118140 |
77 | 2 | |
Shoulder arthroplasty, Therapy interrupted, |
||||
TERIPARATIDE, |
||||
| 282 | 25107718 |
US |
||
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 283 | 25108245 |
US |
1 | |
Therapy interrupted, |
||||
AVACOPAN, |
||||
| 284 | 25108816 |
US |
2 | |
Burns third degree, Therapy interrupted, Product use issue, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, OXYGEN, 0XYGEN, MELOXICAM, TIOTROPIUM BROMIDE INHALATION SPRAY, AMLODIPINE BESYLATE, ESCITALOPRAM OXALATE, ESCITALOPRAM, TADALAFIL, ALBUTEROL SULFATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, FUROSEMIDE, GABAPENTIN, VALSARTAN, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, |
||||
| 285 | 25108843 |
CA |
||
Abdominal pain upper, Nausea, Malaise, Blood cholesterol increased, Weight increased, Therapy interrupted, Intentional dose omission, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, ROSUVASTATIN, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, |
||||
| 286 | 25118058 |
67 | 2 | |
Malaise, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 287 | 25103027 |
US |
1 | |
Dementia with Lewy bodies, Parkinson^s disease, Parkinsonism, Ill-defined disorder, Blood pressure increased, Fall, Product supply issue, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 288 | 25103219 |
US |
||
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 289 | 25103551 |
US |
2 | |
Therapy interrupted, |
||||
| 290 | 25103607 |
US |
80 | 1 |
Therapy interrupted, |
||||
| 291 | 25103824 |
US |
||
Therapy interrupted, |
||||
BOSENTAN, |
||||
| 292 | 25103825 |
US |
||
Therapy interrupted, |
||||
BOSENTAN, |
||||
| 293 | 25104438 |
US |
65 | 1 |
Product prescribing issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 294 | 25104621 |
US |
63 | 1 |
Diarrhoea, Ophthalmic migraine, Blood phosphorus decreased, Nasal dryness, Blood potassium decreased, Therapy interrupted, Intentional underdose, Fatigue, Inappropriate schedule of product administration, Paranasal sinus hyposecretion, Dry mouth, Dry skin, Weight increased, Trigger finger, Tendon pain, Nausea, Tendonitis, Stomatitis, Ear infection, Hyperphagia, Infection, Impaired healing, |
||||
TAMOXIFEN CITRATE, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, LOSARTAN, |
||||
| 295 | 25104778 |
US |
55 | 2 |
Pain, Product dose omission issue, Therapy interrupted, Condition aggravated, |
||||
ABATACEPT, |
||||
| 296 | 25105018 |
US |
2 | |
Pneumonia, Off label use, Therapy interrupted, |
||||
CENEGERMIN-BKBJ, ABATACEPT, |
||||
| 297 | 25105086 |
BR |
10 | 2 |
Inappropriate schedule of product administration, Therapy interrupted, Product availability issue, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 298 | 25106222 |
US |
65 | 2 |
Atrial fibrillation, Cardiac failure, Therapy interrupted, Hunger, Rash pruritic, Thyroid disorder, Urticaria, Anxiety, Gastrointestinal disorder, Emotional distress, Weight increased, Headache, Insomnia, Nausea, Depressed mood, Arthralgia, Back pain, |
||||
GABAPENTIN, LEVOTHYROXINE, ERGOCALCIFEROL, |
||||
| 299 | 25106263 |
US |
61 | 1 |
Therapy interrupted, |
||||
ABATACEPT, |
||||
| 300 | 25106513 |
CO |
39 | 2 |
Pyelocaliectasis, Dysgeusia, Application site discolouration, Papule, Skin exfoliation, Pain of skin, Pain, Somnolence, Treatment noncompliance, Therapy interrupted, Accidental exposure to product, Wrong technique in product usage process, Arthropathy, Osteoarthritis, Erythema, Pruritus, |
||||
MECHLORETHAMINE HYDROCHLORIDE, MECHLORETHAMINE HYDROCHLORIDE, MECHLORETHAMINE HYDROCHLORIDE, ESZOPICLONE, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, ESCITALOPRAM OXALATE, ESCITALOPRAM, QUETIAPINE FUMARATE, QUETIAPINE, SERTRALINE HYDROCHLORIDE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28